US EditionGene therapy AAV-GAD wins RMAT designation for Parkinson’s disease
Summary by Parkinson's News Today
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Gene therapy AAV-GAD wins RMAT designation for Parkinson’s disease
The U.S. Food and Drug Administrated (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) status to AAV-GAD, MeiraGTx’s gene therapy for Parkinson’s disease, the company has announced. The designation was granted based on data from three clinical studies showing the treatment eased motor symptoms and improved the quality of life of people with Parkinson’s. The company is now in regulatory discussions to initiate a Phase 3 study this y…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
